Literature DB >> 21531698

Small-intestinal rhabdoid gastrointestinal stromal tumor (GIST): mutation analysis and clinical implications of a rare morphological variant.

Joshua Anspach Hanson1, Jonathan C Trent, Dan Yang, Kumarasen Cooper.   

Abstract

Rhabdoid features in gastrointestinal stromal tumors (GISTs) are rare. To the authors' knowledge, only 51 cases have been reported. Most of these reports consist of case series in which the rhabdoid GISTs comprise a small proportion of the tumors studied. Information regarding site of origin and clinical behavior is sparse. Although the stomach is the only site of origin documented, most reports do not include this data. Malignancy has not been reported, though follow-up is inadequate in most cases to comment on tumor behavior. Exon 11 mutations comprise all previously described KIT mutations, the majority of which are deletions. The authors present the case of a malignant small-intestinal rhabdoid GIST that recurred twice following resection and treatment with tyrosine kinase inhibitors. The tumor harbored a KIT exon 11, 579-580 LY insertion that, to the authors' knowledge, has not been previously reported. This case is the first rhabdoid GIST described in the small intestine and is the first to show documented evidence of malignancy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21531698     DOI: 10.1177/1066896911404413

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  4 in total

1.  Undifferentiated large cell/rhabdoid carcinoma presenting in the intestines of patients with concurrent or recent non-small cell lung cancer (NSCLC): clinicopathologic and molecular analysis of 14 cases indicates an unusual pattern of dedifferentiated metastases.

Authors:  Abbas Agaimy; Ondrej Daum; Michal Michal; Mona W Schmidt; Robert Stoehr; Arndt Hartmann; Gregory Y Lauwers
Journal:  Virchows Arch       Date:  2021-01-27       Impact factor: 4.064

2.  Rhabdomyosarcomatous Transformation of a Gastrointestinal Stromal Tumor following Treatment with Imatinib.

Authors:  Xiaoyin Jiang; H Bryan Anderson; Cynthia D Guy; Paul J Mosca; Richard F Riedel; Diana M Cardona
Journal:  Case Rep Oncol Med       Date:  2015-01-28

3.  Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K).

Authors:  Gianluca Spitaleri; Roberto Biffi; Massimo Barberis; Caterina Fumagalli; Francesca Toffalorio; Chiara Catania; Cristina Noberasco; Chiara Lazzari; Filippo de Marinis; Tommaso De Pas
Journal:  Onco Targets Ther       Date:  2015-08-18       Impact factor: 4.147

4.  Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study.

Authors:  Jing Qi; He-Li Liu; Feng Ren; Sheng Liu; Wei Shi; Wei-Hang Liu; Gao-Qiang Cai; Guo-Qing Liao
Journal:  World J Surg Oncol       Date:  2020-04-07       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.